Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHF 6333

Next Previous
X
Search
Drug Profile

CHF 6333

Alternative Names: CHF-6333

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Antibronchitics; Antifibrotics; Esters; Fluorinated hydrocarbons; Nitriles; Pyrimidines; Quaternary ammonium compounds; Small molecules; Triazoles
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bronchiectasis
  • No development reported Cystic fibrosis

Most Recent Events

  • 29 Nov 2023 Phase-I/II clinical trials in Bronchiectasis in United Kingdom (Inhalation) (NCT06166056)
  • 08 Feb 2023 Clinical trials in Bronchiectasis (Non-cystic fibrosis-related) in USA (Inhalation) (Chiesi pipeline, February 2023)
  • 05 Sep 2022 Preclinical trials in Bronchiectasis (Non-cystic fibrosis-related) in USA (Inhalation) (Chiesi USA pipeline, September 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top